NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Forecast, Price & News $3.26 -0.08 (-2.40%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$3.25▼$3.4050-Day Range$3.26▼$3.8652-Week Range$2.90▼$6.45Volume15,071 shsAverage Volume46,708 shsMarket Capitalization$101.29 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Anixa Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside222.1% Upside$10.50 Price TargetShort InterestHealthy2.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.18Based on 6 Articles This WeekInsider TradingSelling Shares$42,126 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.32) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector310th out of 964 stocksPharmaceutical Preparations Industry124th out of 438 stocks 3.5 Analyst's Opinion Consensus RatingAnixa Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Anixa Biosciences has a forecasted upside of 222.1% from its current price of $3.26.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.12% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Anixa Biosciences has recently decreased by 4.00%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANIX. Previous Next 4.0 News and Social Media Coverage News SentimentAnixa Biosciences has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Anixa Biosciences this week, compared to 1 article on an average week.Search Interest4 people have searched for ANIX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have sold 110.42% more of their company's stock than they have bought. Specifically, they have bought $20,020.00 in company stock and sold $42,126.00 in company stock.Percentage Held by Insiders20.40% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.78% of the stock of Anixa Biosciences is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.32) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anixa Biosciences (NASDAQ:ANIX) StockAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Read More ANIX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIX Stock News HeadlinesSeptember 22, 2023 | americanbankingnews.comAnixa Biosciences, Inc. Forecasted to Post FY2023 Earnings of ($0.32) Per Share (NASDAQ:ANIX)September 21, 2023 | finance.yahoo.comANIXA BIOSCIENCES INC (ANIX) Upgraded to Buy: What Does It Mean for the Stock?September 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 19, 2023 | finance.yahoo.comAnixa Biosciences Establishes Cancer Business Advisory BoardSeptember 19, 2023 | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Receives "Buy" Rating from HC WainwrightSeptember 19, 2023 | finance.yahoo.comThe 3 Most Undervalued Cheap Stocks to Buy in September 2023September 18, 2023 | markets.businessinsider.comAnixa Biosciences (ANIX) Receives a Buy from H.C. WainwrightSeptember 10, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn SituationSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 31, 2023 | msn.comAnixa Biosciences (ANIX) Price Target Increased by 14.29% to 12.24August 31, 2023 | finance.yahoo.comAnixa Biosciences to Participate in September Investor ConferencesAugust 28, 2023 | finance.yahoo.comAnixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical TrialAugust 25, 2023 | msn.comAnixa Biosciences: Early Stage, Low Cash. Does It Matter?August 16, 2023 | msn.comSmall Biotech Company Hopes its Vaccine Will End Breast CancerAugust 15, 2023 | msn.comBiotech Company Hopes to Eliminate Breast Cancer with a VaccineAugust 14, 2023 | finance.yahoo.comAnixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR SummitAugust 10, 2023 | finanznachrichten.deAnixa Biosciences, Inc.: Could Anixa Biosciences Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?August 10, 2023 | finance.yahoo.comCould Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?August 9, 2023 | benzinga.comCould Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?July 28, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Anixa Biosciences (ANIX), Roche Holding AG (OtherRHHVF) and Bristol-Myers Squibb (BMY)July 27, 2023 | finance.yahoo.comAnixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine TechnologyJuly 25, 2023 | msn.comOhio woman part of groundbreaking breast cancer vaccine trialJuly 24, 2023 | msn.comNE Ohio woman part of groundbreaking breast cancer vaccine trialJuly 24, 2023 | finance.yahoo.comGilead (GILD) Ends Myelodysplastic Syndromes Study on MagrolimabJuly 24, 2023 | benzinga.comAnixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively BuyingJuly 21, 2023 | finance.yahoo.comVir Biotechnology (VIR) Down on Influenza Study FailureJuly 12, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Anixa Biosciences (ANIX)See More Headlines Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIX Company Calendar Last Earnings8/31/2021Today9/27/2023Fiscal Year End10/31/2023Next Earnings (Estimated)1/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANIX CUSIPN/A CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees4Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+222.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,600,000.00 Net MarginsN/A Pretax Margin-5,113.33% Return on Equity-40.14% Return on Assets-37.55% Debt Debt-to-Equity RatioN/A Current Ratio14.22 Quick Ratio14.22 Sales & Book Value Annual Sales$510,000.00 Price / Sales198.60 Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book3.54Miscellaneous Outstanding Shares31,070,000Free Float24,732,000Market Cap$101.29 million OptionableNot Optionable Beta0.94 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Amit Kumar Ph.D. (Age 59)Chairman & CEO Comp: $1.07MMr. Michael J. Catelani CPA (Age 56)MBA, Pres, COO, CFO & Corp. Sec. Comp: $550.96kMr. John Roop (Age 73)Sr. VP of Engineering Dr. Thomas Schlumpberger Ph.D. (Age 57)Exec. VP of Diagnostics Dr. Pamela D. Garzone Ph.D. (Age 68)Chief Devel. Officer & Chair Breast Cancer Clinical Advisory Board Key CompetitorsAquestive TherapeuticsNASDAQ:AQSTMilestone PharmaceuticalsNASDAQ:MISTI-MabNASDAQ:IMABMediciNovaNASDAQ:MNOVAbeona TherapeuticsNASDAQ:ABEOView All CompetitorsInsiders & InstitutionsTyler Stone Wealth ManagementBought 21,008 shares on 8/15/2023Ownership: 0.068%Citadel Advisors LLCSold 6,200 shares on 8/15/2023Ownership: 0.000%BlackRock Inc.Bought 4,210 shares on 8/11/2023Ownership: 0.812%Northern Trust CorpSold 4,611 shares on 8/11/2023Ownership: 0.174%JPMorgan Chase & Co.Bought 21,639 shares on 8/11/2023Ownership: 0.088%View All Insider TransactionsView All Institutional Transactions ANIX Stock - Frequently Asked Questions Should I buy or sell Anixa Biosciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIX shares. View ANIX analyst ratings or view top-rated stocks. What is Anixa Biosciences' stock price forecast for 2023? 2 Wall Street analysts have issued 1 year target prices for Anixa Biosciences' shares. Their ANIX share price forecasts range from $9.00 to $12.00. On average, they expect the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 222.1% from the stock's current price. View analysts price targets for ANIX or view top-rated stocks among Wall Street analysts. How have ANIX shares performed in 2023? Anixa Biosciences' stock was trading at $4.25 at the beginning of the year. Since then, ANIX shares have decreased by 23.3% and is now trading at $3.26. View the best growth stocks for 2023 here. When is Anixa Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 3rd 2024. View our ANIX earnings forecast. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences, Inc. (NASDAQ:ANIX) released its quarterly earnings results on Tuesday, August, 31st. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL), Akoustis Technologies (AKTS), Akero Therapeutics (AKRO), Aimmune Therapeutics (AIMT) and Advanced Emissions Solutions (ADES). What is Anixa Biosciences' stock symbol? Anixa Biosciences trades on the NASDAQ under the ticker symbol "ANIX." Who are Anixa Biosciences' major shareholders? Anixa Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.98%), BlackRock Inc. (0.81%), Renaissance Technologies LLC (0.19%), Northern Trust Corp (0.17%), JPMorgan Chase & Co. (0.09%) and Tyler Stone Wealth Management (0.07%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Emily Gottschalk, Lewis H Titterton Jr and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anixa Biosciences' stock price today? One share of ANIX stock can currently be purchased for approximately $3.26. How much money does Anixa Biosciences make? Anixa Biosciences (NASDAQ:ANIX) has a market capitalization of $101.29 million and generates $510,000.00 in revenue each year. The company earns $-13,600,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. How can I contact Anixa Biosciences? Anixa Biosciences' mailing address is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. The official website for the company is www.anixa.com. The company can be reached via phone at (408) 708-9808, via email at mcatelani@ituscorp.com, or via fax at 631-549-5974. This page (NASDAQ:ANIX) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.